Status:
COMPLETED
Intensity Modulated Radiation Therapy for Head and Neck Cancer
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Nasopharyngeal Neoplasms
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Many normal tissues, including the eyes, brain, and spinal cord are very close to cancers in the nasopharynx. The dose of radiation delivered to the cancer is limited by tolerance of these normal tiss...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Confirmed histopathologic diagnosis of nasopharyngeal squamous cell carcinoma requiring primary radiation
- less than 70 yrs of age
- Stage T1-T4; N0-N3; M0
- KPS less than 70
- no prior RT to H\&N or chemotherapy for H\&N
- no other malignancy except non-melanomatous skin cancer
- no distant mets
- no contraindication to RT or chemotherapy
- adequate organ function
- informed consent
- Exclusion Criteria
- Major medical or psychiatric illness, which would interfere with either completion of therapy and follow-up or with full and complete understanding of the risks and potential complications of the therapy.
Exclusion
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00188877
Start Date
June 1 2003
End Date
June 1 2019
Last Update
December 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9